The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I trial of combined tivozanib (AV-951) and temsirolimus therapy in patients (pts) with renal cell carcinoma (RCC).
Fairooz F. Kabbinavar
No relevant relationships to disclose
Sandy Srinivas
No relevant relationships to disclose
Ralph J. Hauke
No relevant relationships to disclose
Robert J. Amato
No relevant relationships to disclose
Brooke Esteves
No relevant relationships to disclose
Reena Dhillon
No relevant relationships to disclose
Monette M. Cotreau
No relevant relationships to disclose
Mohammed Al-Adhami
No relevant relationships to disclose
Pankaj Bhargava
No relevant relationships to disclose
Mayer N. Fishman
No relevant relationships to disclose